#USA #San Diego #Inhibrx Biosciences #INBRX-109 #Chondrosarcoma

Inhibrx Reports Impressive Third Quarter 2025 Financial Outcomes and Clinical Progress

Inhibrx Biosciences, Inc. (Nasdaq: INBX) has recently shared its financial performance for the third quarter of 2025, revealing notable developments in its clinical pipeline. This biopharmaceutical company, which specializes in innovative treatments, has made strides since its spin-off from its former parent company in May 2024. Following the completion of the INBRX-101 transaction with Sanofi S.A., Inhibrx is now focusing on two key programs that are currently undergoing clinical trials.

Recent Corporate Highlights

On October 23, 2025, Inhibrx achieved a significant milestone by announcing promising topline results from its registrational trial of ozekibart (INBRX-109), aimed at treating chondrosarcoma. This drug has successfully met its primary endpoint, showcasing a statistically significant and clinically meaningful improvement in median progression-free survival when compared to placebo. Additionally, key secondary endpoints have reinforced these findings by demonstrating considerable enhancements in disease control and the overall quality of life for patients.

Furthermore, Inhibrx plans to file a biologics license application with the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. Preliminary data from expansion cohorts for colorectal cancer and Ewing sarcoma have also displayed high response and disease control rates for patients with difficult-to-treat conditions, marking a pivotal advancement in Inhibrx's journey.

Financial Performance Overview

As of September 30, 2025, Inhibrx had cash and cash equivalents totaling $153.1 million, a decrease from $186.6 million on June 30, 2025. Research and development (R&D) expenses for this quarter were reported at $28.5 million, a decline from $38.9 million during the same period in 2024. This decrease primarily reflects a reduction in process development and manufacturing activities carried out by contract development and manufacturing organizations (CDMO) in connection with the ozekibart clinical trial. Additionally, personnel-related expenses diminished due to a reduced workforce during this period.

General and administrative expenses for the third quarter of 2025 amounted to $5.3 million, down from $7.9 million in the previous year. This drop can be attributed to decreased legal costs following the resolution of legal disputes and reductions in personnel costs due to a lower headcount. Other expenses stood at $1.4 million, a significant shift from $2.9 million in income reported during the third quarter of 2024, largely resulting from interest expenses on the company's outstanding debt.

The net loss for this period was $35.3 million, translating to a loss of $2.28 per share, showing an improvement compared to a loss of $43.9 million or $2.84 per share in the same quarter of the previous year.

Company Overview and Future Outlook

Inhibrx is a forward-thinking, clinical-stage biopharmaceutical company that is developing a diverse range of novel biologic therapies. With a strong focus on protein engineering technologies, Inhibrx aims to create targeted treatments that can effectively address various complex diseases. Since its formation as a direct subsidiary of Inhibrx, Inc., the company has restructured and streamlined its operations to better position itself for future growth.

Looking ahead, Inhibrx is optimistic about the future of its therapeutic candidates, particularly ozekibart (INBRX-109), which shows great potential based on early trial results. The company remains committed to advancing its clinical programs and achieving regulatory approval for its innovative therapies.

For more information, please visit Inhibrx's official website.

Forward-Looking Statements:
Certain statements made in this press release about future forecasts and expected outcomes regarding Inhibrx’s performance are based on current beliefs and may be subject to uncertainties. These forward-looking statements may vary from actual results due to various business risks, including potential changes in clinical trial outcomes, regulatory approvals, and market conditions. Investors are urged to consider these factors when evaluating the company’s future prospects.